The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2025 | Updates in the field of CMML: changes in diagnostic criteria & the growing number of clinical trials
In this video, Eric Padron, MD, Moffitt Cancer Center, Tampa, FL, briefly highlights some of the recent updates in the field of chronic myelomonocytic leukemia (CMML), including the evolving diagnostic criteria and the growing number of clinical trials investigating novel therapeutic approaches in this rare disease. Despite many open questions remaining, Dr Padron notes that there is a growing community of researchers and industry partners working on developing new treatments for CMML. This interview took place at the 2nd Annual MPN Workshop of the Carolinas, held in Charlotte, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So, I think the major update over the last two years is how we diagnose CMML, which has been defined a lot more broadly than it used to. And so, just by definition, a lot more of our patients will be classified as CMML. Is it the right criteria? Should we change it? There’s still a lot of open questions, but how we define and how we diagnose CMML has changed...
So, I think the major update over the last two years is how we diagnose CMML, which has been defined a lot more broadly than it used to. And so, just by definition, a lot more of our patients will be classified as CMML. Is it the right criteria? Should we change it? There’s still a lot of open questions, but how we define and how we diagnose CMML has changed. And then I think what I tell people is even though there are so many questions to be answered, I think more than ever for a variety of reasons, there is a growing community of CMML researchers and industry partners who are really interested in developing new drugs for this disease. And we desperately need some. So while we’re in early stages of a variety of clinical trials in CMML, often many of these clinical trials are actually repurposing a lot of the drugs that have been approved for myeloproliferative neoplasms. But I’m very optimistic that, you know, in the next year or two, we’re going to see, you know, many CMML, dozens of CMML studies in the near future.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
